Efficacy comparison of toripalimab versus pembrolizumab in neoadjuvant treatment of breast cancer: impact of chemotherapy regimen and sequence on pathologic complete response
Toripalimab demonstrated non-inferior efficacy compared to pembrolizumab in the neoadjuvant treatment of breast cancer. Chemotherapy sequence-particularly the TCb-EC regimen-significantly predicted pCR, while immunotherapy cycle number and platinum use did not influence pathologic outcomes. These real-world findings support toripalimab's clinical use and underscore the importance of optimizing chemoimmunotherapy sequencing.
Authors
- Yunjiao Zhang (ORCID: https://orcid.org/0000-0002-6465-7488)
- Xun Zhang (ORCID: https://orcid.org/0000-0002-8545-6263)
- Chutuo Liu
- Xi Chen (ORCID: https://orcid.org/0000-0002-3160-614X)
- Bo Zhang (ORCID: https://orcid.org/0000-0002-0804-6404)
- Zhe Wang (ORCID: https://orcid.org/0000-0003-3173-9695)
- Rui Ling (ORCID: https://orcid.org/0000-0002-2774-0119)
Institutions
- Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
- Xijing Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-19
- DOI
- https://doi.org/10.3389/fonc.2025.1699963
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Key Research and Development Projects of Shaanxi Province